These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 857860)

  • 21. Environmental conditions favorable for tumor progression in peritoneal cavity induced by peritoneal cells without tumor selectivity.
    Segawa K; Ueno Y; Kataoka T
    Jpn J Exp Med; 1989 Jun; 59(3):127-33. PubMed ID: 2681889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STUDIES OF LEUKEMIA L1210 HOMOGRAFT IN SWISS HA-ICR MICE.
    BRADNER WT; BACHMAN S; PINDELL MH
    Cancer Chemother Rep; 1964 Jul; 39():21-39. PubMed ID: 14201273
    [No Abstract]   [Full Text] [Related]  

  • 23. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus).
    Takeyama H; Kawashima K; Yamada K; Ito Y
    Gan; 1979 Aug; 70(4):493-501. PubMed ID: 229053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population changes of a rat leukemia by different routes of transplantation.
    Ishidate M; Aoshima M; Sakurai Y
    J Natl Cancer Inst; 1974 Sep; 53(3):773-81. PubMed ID: 4528680
    [No Abstract]   [Full Text] [Related]  

  • 25. Decrease in oncogenic potential of L1210 leukemia by triazenes.
    Schmid FA; Hutchison DJ
    Cancer Res; 1973 Sep; 33(9):2161-5. PubMed ID: 4725373
    [No Abstract]   [Full Text] [Related]  

  • 26. [Non-phosphorylative transglycosylation in the serum and liver of mice with transplantable leukemia P388 and L1210].
    Sobiech KA; Madej JA; Kotoński B
    Pol Arch Weter; 1986; 26(3-4):49-58. PubMed ID: 3438186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of red blood cell deformability by tumor growth.
    Cohen MH
    J Natl Cancer Inst; 1979 Aug; 63(2):525-6. PubMed ID: 287842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of growth inhibition by glucocorticoid on L5178Y and L1210 lymphoblasts in vivo.
    Kido H; Tomihara Y; Watanabe I; Ohsawa N; Katunuma N
    Cancer Res; 1979 Aug; 39(8):3258-61. PubMed ID: 222447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effects of methotrexate. Inhibition of DNA synthesis and cell death in sensitive and resistant L1210 ascites populations.
    Hofer KG
    Chemotherapy; 1972; 17(1):59-70. PubMed ID: 5009468
    [No Abstract]   [Full Text] [Related]  

  • 30. Active immunotherapy of mouse RC 19 and E female K1 leukaemias applied after the intravenous transplantation of the tumour cells.
    Mathé G; Pouillart P; Lapeyraque F
    Experientia; 1971 Apr; 27(4):446-7. PubMed ID: 5581118
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization of a monoclonal antibody to L1210 leukaemia.
    Testorelli C; Morelli S; Goldin A; Nicolin A
    Br J Cancer; 1982 Mar; 45(3):395-402. PubMed ID: 7073934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of N-trifuloroacetyladriamycin-14-valerate.
    Pratesi G; Casazza AM; Di Marco A
    Cancer Treat Rep; 1978 Jan; 62(1):105-10. PubMed ID: 626988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity and antitumor activity of gallium nitrate and periodically related metal salts.
    Hart MM; Smith CF; Yancey ST; Adamson RH
    J Natl Cancer Inst; 1971 Nov; 47(5):1121-7. PubMed ID: 4330799
    [No Abstract]   [Full Text] [Related]  

  • 34. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Acta Pathol Microbiol Scand A; 1973 Sep; 81(5):715-24. PubMed ID: 4771975
    [No Abstract]   [Full Text] [Related]  

  • 35. Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)-quinazolinone (NSC-145669).
    Neil GL; Li LH; Buskirk HH; Moxley TE
    Cancer Chemother Rep; 1972 Apr; 56(2):163-73. PubMed ID: 5043224
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of a delta 5-homo-aza-steroidal ester in P388 and L1210 murine leukemias.
    Catsoulacos P; Camoutsis C; Wampler GL
    Oncology; 1982; 39(1):59-60. PubMed ID: 7058047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
    Fox JJ; Falco EA; Wempen I; Pomeroy D; Dowling MD; Burchenal JH
    Cancer Res; 1972 Oct; 32(10):2269-72. PubMed ID: 4673145
    [No Abstract]   [Full Text] [Related]  

  • 38. CATALASE ACTIVITY IN MOUSE LEUKEMIA L1210.
    LOTTSFELDT FI; PEHOUSHEK C; KRIVIT W
    Cancer Res; 1965 Feb; 25():370-3. PubMed ID: 14264061
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice.
    Berd DA; Mitchell MS
    Cancer Res; 1976 Nov; 36(11 Pt 1):4119-24. PubMed ID: 975053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the biological effects of four irreversible inhibitors of ornithine decarboxylase in two murine lymphocytic leukemia cell lines.
    Pera PJ; Kramer DL; Sufrin JR; Porter CW
    Cancer Res; 1986 Mar; 46(3):1148-54. PubMed ID: 3080234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.